Gamolenic Acid

Summary

Gamolenic Acid (CHEMBL464982) is a phase-3 clinical-stage small molecule (ATC D11AX02); indicated across 2 conditions including rheumatoid arthritis and asthma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: D11AX02 (+1 more)
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 278.4 Da · C18H30O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL464982
Name	Gamolenic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5280933
ChEBI	CHEBI:28661
ATC	D11AX02, D11AX52
Molecular formula	C18H30O2
Molecular weight	278.4
InChIKey	VZCCETWTMQHEPK-QNEBEIHSSA-N

SMILES: CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O

IUPAC name: (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid

ChEBI definition: A C18, ω-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.

Other ChEBI roles (chemical / environmental): human metabolite, plant metabolite, mouse metabolite.

Also known as: .gamma.-linolenic acid, 18:3(N-6), Acide gamolenique, Acido gamolenico, C18:3 (n-6), Delta-linolenic acid, Efamast 40, Efamast 80, Epoc, Epogam, Epogam 40, Epogam 80

Patent coverage: 12,072 distinct patent families (26,552 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Beta-lactamase, Estrogen receptor, Coagulation factor VII/tissue factor, Prostaglandin G/H synthase 1, Peroxisome proliferator-activated receptor gamma, Peroxisome proliferator-activated receptor alpha, Caspase-6, Peroxisome proliferator-activated receptor delta.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARA	6.57	IC50	270	nM	CHEMBL_ACT_12477762
PPARA	6.57	IC50	270	nM	CHEMBL_ACT_12604668
CASP6	6.3	AC50	505	nM	CHEMBL_ACT_14373717
PPARD	6.12	IC50	750	nM	CHEMBL_ACT_12604636
PPARG	5.66	IC50	2200	nM	CHEMBL_ACT_12604652
FFAR1	5.33	EC50	4620	nM	CHEMBL_ACT_16454738
PTGS1	5.31	AC50	4911	nM	CHEMBL_ACT_25205558
P00811	5.3	Potency	5012	nM	CHEMBL_ACT_4657859

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
asthma	1	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00878670	PHASE4	COMPLETED	Investigation of Efficacy and Safety of EPOGAM
NCT01179971	PHASE2	COMPLETED	n-3 and n-6 Fatty Acids in Rheumatoid Arthritis
NCT00004420	Not specified	COMPLETED	Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis
NCT04481724	Not specified	COMPLETED	Gamma-linolenic Acid Supplementation Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).